Lymphoma Clinical Trials

Showing 2881-2900 of 3,379 trials

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

NCT01689220

The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).

Peripheral T-cell Lymphoma

Solasia Pharma K.K.6 participantsStarted Sep 2012

Seoul, South Korea

UNKNOWNPhase 2

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma

NCT01178645

The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.

Non-Hodgkin Lymphoma

Seoul National University Hospital42 participantsStarted Jul 2010

Busan, South Korea • Seoul, South Korea • Seoul, South Korea +2 more locations

COMPLETED

Metabolic Syndrome in Childhood Cancer Survivors

NCT00920738

RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood cancer may help doctors learn more about the disease. PURPOSE: This clinical trial is studying metabolic syndrome in survivors of childhood cancer and in their healthy sisters and brothers.

Brain and Central Nervous System TumorsLeukemiaLymphoma+2 more

University of Minnesota512 participantsStarted Apr 2005

Minneapolis, Minnesota, United States

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma

Metabolic Syndrome in Childhood Cancer Survivors

Related Searches

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

AZD6738 First Time in Patient Multiple Ascending Dose Study

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia